BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

The miR-302-367 cluster as a potential stemness regulator in ESCs

(2011) Alicia Barroso-del Jesus et al.   CELL CYCLE

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) H. Becker et al.   BLOOD

Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development

(2010) Urban Gullberg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

(2009) Carlos Santamaría et al.   ANNALS OF HEMATOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma

(2009) Shuhei Komatsu et al.   CARCINOGENESIS

BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis

(2009) M. A. EID et al.   International Journal of Laboratory Hematology

Prognostic Importance ofMN1Transcript Levels, and Biologic Insights FromMN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2009) Christian Langer et al.   JOURNAL OF CLINICAL ONCOLOGY

ERGExpression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis ofERG, MN1, andBAALCTranscript Levels Using Oligonucleotide Microarrays

(2009) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage

(2009) E. A. Kruse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

(2008) C. Langer et al.   BLOOD

Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With,CEBPAMutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

(2008) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Guido Marcucci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

(2008) Darren J. Burgess et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

miR-148 targets human DNMT3b protein coding region

(2008) A. M. Duursma et al.   RNA